33620 Results

People

  1. Ladanyi
    Ladanyi
  2. Giralt
    Giralt
  3. Motzer
    Motzer
  4. Reuter
    Reuter
  5. Perales
    Perales
  6. Scher
    Scher
  7. Zelenetz
    Zelenetz
  8. Berger
    Berger
  9. Al-Ahmadie
    Al-Ahmadie
  10. O'Reilly
    O'Reilly

Groups

  1. Department of Medicine (15822)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7076)
  4. Hematologic Malignancies, Division of (6210)
  5. Center for Hematologic Malignancies (6017)
  6. Survivorship Research (5192)
  7. Department of Pathology and Laboratory Medicine (5172)
  8. Surgery (4871)
  9. Sloan Kettering Institute Faculty (3826)
  10. Sloan Kettering Institute Postdocs (3612)
  1. "Meeting abstract"
Formats
  1. Meeting Abstract (33620)
Groups
  1. Department of Medicine (15822)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7076)
  4. Hematologic Malignancies, Division of (6210)
  5. Center for Hematologic Malignancies (6017)
  6. Survivorship Research (5192)

More Groups

People
  1. Marc Ladanyi (641)
  2. Sergio Giralt (632)
  3. Robert Motzer (574)
  4. Victor Reuter (568)
  5. Miguel-Angel Perales (482)
  6. Howard Scher (463)

More People

Years
  1. 2025 (295)
  2. 2024 (1694)
  3. 2023 (1954)
  4. 2022 (2196)
  5. 2021 (1731)
  6. 2020 (1901)

More Years

Publications
  1. Journal of Clinical Oncology (6252)
  2. Blood (3939)
  3. Laboratory Investigation (1846)
  4. Cancer Research (1822)
  5. International Journal of Radiation Oncology, Biology, Physics (1643)
  6. Modern Pathology (1494)

More Publications

Publishers
  1. American Society of Clinical Oncology (6251)
  2. Elsevier Inc. (4694)
  3. American Society of Hematology (3939)
  4. American Association for Cancer Research (3045)
  5. Nature Publishing Group (2151)
  6. Oxford University Press (2096)

More Publishers

Results (33620)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • HJKC3-007: Outcomes of patients with chronic myeloid leukemia in chronic phase treated with asciminib and other tyrosine kinase inhibitors in routine clinical practice
    Meeting Abstract

    Mauro, M.; Atallah, E. L.; Thompson, J. E.; Gao, Y.; Visotcky, A.; Giever, E.; Baim, A.; Akinola, I.; Larson, R. A.; Jamy, O.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Durable efficacy and manageable safety in patients age≥75 years with relapsed/refractory large B-cell lymphoma treated with tisagenlecleucel in the real-world setting
    Meeting Abstract

    Landsburg, D. J.; Heim, M.; Moskop, A.; Foley, S. R.; Hill, B. T.; Schofield, G.; Jacobson, C.; Jaglowski, S. M.; Locke, F. L.; Ram, R.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • A phase 1a/b trial of luxeptinib (CG-806) in patients with relapsed/refractory B-cell malignancies or acute myeloid leukemia and evaluation of new G3 formulation
    Meeting Abstract

    Goldberg, A. D.; Samaniego, F.; Ohanian, M.; Koller, P. B.; Chandhok, N. S.; Sadiq, A. A.; Mahadevan, D.; Cherry, M. A.; Altman, J. K.; Burke, J. M.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Preliminary safety, pharmacokinetics, pharmacodynamics and clinical activity of KT-333, a targeted protein degrader of STAT3, in patients with relapsed or refractory lymphomas, large granular lymphocytic leukemia, and solid tumors
    Meeting Abstract

    Shastri, A.; Feldman, E. J.; Starodub, A. N.; Feldman, T.; Rodriguez, C. P.; Epstein-Peterson, Z. D.; Stevens, D. A.; Olszewski, A. J.; Huen, A. O.; Porcu, P.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • PROMMIS trial prospectively demonstrates the efficacy of SKY92 risk stratification in newly diagnosed multiple myeloma patients
    Meeting Abstract

    Biran, N.; Dhakal, B.; Niesvizky, R.; Lentzsch, S.; McKay, J. T.; Vesole, D. H.; Nooka, A. K.; Paul, B.; Hari, P. N.; Stork-Sloots, L.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Impact of diagnosis to treatment interval on outcomes in patients with newly diagnosed marginal zone lymphoma - A US multisite study
    Meeting Abstract

    Epperla, N.; Annunzio, K.; Shouse, G. P.; Grover, N. S.; Torka, P.; Watkins, M. P.; Anampa-Guzmán, A. C.; Oh, T. S.; Reves, H.; Tavakkoli, M.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Patient-reported outcomes (PROs) among patients with previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) receiving pirtobrutinib: Analysis from the BRUIN phase 1/2 study
    Meeting Abstract

    Coombs, C. C.; Woyach, J. A.; Brown, J. R.; Ghia, P.; Roeker, L. E.; Patel, K.; Eyre, T. A.; Tam, C. S.; Seymour, J. F.; Shah, N. N.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Revumenib monotherapy in patients with relapsed/refractory KMT2Ar acute leukemias: Efficacy and safety results from the AUGMENT-101 phase 1/2 study
    Meeting Abstract

    Aldoss, I.; Issa, G. C.; Thirman, M. J.; DiPersio, J.; Arellano, M.; Blachly, J. S.; Mannis, G.; Perl, A.; Dickens, D.; McMahon, C. M.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Lisocabtagene maraleucel (liso-cel) in patients (pts) with R/R MCL: Subgroup analyses in pts with high-risk disease features from the MCL cohort of the TRANSCEND NHL 001
    Meeting Abstract

    Palomba, M. L.; Siddiqi, T.; Gordon, L. I.; Kamdar, M.; Lunning, M. A.; Hirayama, A. V.; Abramson, J. S.; Arnason, J. E.; Ghosh, N.; Mehta, A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Outcomes of patients with relapsed/refractory lymphoplasmacytic lymphoma treated with venetoclax: A multicenter retrospective analysis
    Meeting Abstract

    Sawalha, Y.; Sarosiek, S. R.; Welkie, R. L.; Seif, S.; Thapa, S.; Zanwar, S.; Cahill, K.; Treitman, R.; Shah, H.; Arora, S.; more...
    Blood (2023)

    Fulltext@MSK | Save